RUNX1 and endometrial carcinoma: Aberrant expression of Aml1 in breast cancer [24] and esophagus adenocarcinoma [25] has been documented; moreover, Aml1 is overexpressed in endometrial carcinoma [26] and downregulated in gastric cancer [27].